Details for Patent: 8,497,284
✉ Email this page to a colleague
Which drugs does patent 8,497,284 protect, and when does it expire?
Patent 8,497,284 protects CABOMETYX and is included in one NDA.
This patent has seventy-four patent family members in seventeen countries.
Summary for Patent: 8,497,284
| Title: | C-met modulators and method of use |
| Abstract: | The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. |
| Inventor(s): | Bannen; Lynne Canne (Lucerne, CA), Chan; Diva Sze-Ming (Oakland, CA), Chen; Jeff (San Francisco, CA), Dalrymple; Lisa Esther (Seattle, WA), Forsyth; Timothy Patrick (Hayward, CA), Huynh; Tai Phat (Oakland, CA), Jammalamadaka; Vasu (Pleasanton, CA), Khoury; Richard George (San Mateo, CA), Leahy; James William (San Leandro, CA), Mac; Morrison B. (San Francisco, CA), Mann; Grace (San Mateo, CA), Mann; Larry W. (Richland, MI), Nuss; John M. (Danville, CA), Parks; Jason Jevious (Sacramento, CA), Takeuchi; Craig Stacy (Burlingame, CA), Wang; Yong (Foster City, CA), Xu; Wei (Danville, CA) |
| Assignee: | Exelixis, Inc. (South San Francisco, CA) |
| Application Number: | 13/249,815 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,497,284 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,497,284
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF RENAL CELL CARCINOMA | ⤷ Sign Up | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB | ⤷ Sign Up | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADVANCED RENAL CELL CARCINOMA | ⤷ Sign Up | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF RENAL CELL CARCINOMA | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,497,284
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2213661 | ⤷ Sign Up | C300678 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2213661 | ⤷ Sign Up | CA 2014 00039 | Denmark | ⤷ Sign Up |
| European Patent Office | 2213661 | ⤷ Sign Up | PA2014033 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2213661 | ⤷ Sign Up | C20140029 00117 | Estonia | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
